These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8018528)

  • 21. Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases.
    Pilati P; Mocellin S; Miotto D; Fittà C; Casara D; Ori C; Scalerta R; Nitti D; Lise M; Rossi CR
    Oncol Rep; 2004 Oct; 12(4):895-901. PubMed ID: 15375519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
    Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
    Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated limb perfusion for melanoma.
    Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
    J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
    Wu ZY; Smithers BM; Parsons PG; Roberts MS
    Br J Cancer; 1997; 75(8):1160-6. PubMed ID: 9099965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
    Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
    Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study.
    Vrouenraets BC; Kroon BB; van de Merwe SA; Klaase JM; Broekmeyer-Reurink MP; van Slooten GW; Nieweg OE; van der Zee J; van Dongen JA
    Eur Surg Res; 1996; 28(3):235-44. PubMed ID: 8738534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?
    McMahon N; Cheng TY; Beasley GM; Spasojevic I; Petros W; Augustine CK; Zipfel P; Padussis JC; Sanders G; Tyler DS
    Ann Surg Oncol; 2009 Apr; 16(4):953-61. PubMed ID: 19184236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb.
    Wu ZY; Smithers BM; Roberts MS
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1131-8. PubMed ID: 9316818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
    Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
    J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of perfusion and infusion in the treatment of malignant melanoma of the lower extremities].
    Meyza J
    Pediatr Pol; 1986 Aug; 61(8):521-3. PubMed ID: 3575001
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.